News

Check out the latest cartoon!

Fellows, residents from around the world show promise for future of retinal research.

The study focused the safety and tolerability of increasing doses of polihexanide eye drops in order to choose a dose that would be tested in a phase III clinical trial in patients with acanthamoeba keratitis.

Once-daily corticosteroid treats pain, inflammation after surgery.

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Noninvasive option reduces IOP in patients with glaucoma.

Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

The Phase 1 clinical trial of EyePoint Pharmaceuticals Inc.’s EYP-1901 is underway. It is a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.

According to investigators, a lack of definitive knowledge about the presence of SARS-CoV-2 in corneal tissues has resulted in the recommendation to avoid using corneal tissue for transplantation when the tissue was obtained from donors with COVID-19 that had been confirmed or those who were exposed to COVID-19.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Emerging technology may facilitate individualized care, disease management.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Organization shines spotlight on frontline heroes during ongoing COVID-19 battle.

For ophthalmologists, practice makes perfect in becoming ambidextrous.

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

In observance of International Holocaust Remembrance Day this January 27, John H. Merey, MD, may be the only Holocaust survivor still in the practice of ophthalmology.

Physician pioneers technique offering higher perspective in surgery, outcomes.

Amid the COVID-19 pandemic, the use of hand sanitizers has increased. However, when they are used improperly, hand sanitizers can damage the eyes. Ophthalmologists are now treating young patients who got the liquid in their eyes.

The investigational therapy met all primary endpoints of absence of inflammation at both Day 8 and Day 15 for the treatment of pain and inflammation following cataract surgery.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.

Sometimes, physicians may find that falling behind is the right thing to do.

Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.

Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.

Higher levels of 3 macular pigments minimize risk of age-related disease.